(Q36878944)

16 August 2017

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

3

F van Rhee

1 reference

16 August 2017

M Pineda-Roman

1

1 reference

16 August 2017

M Zangari

2

1 reference

16 August 2017

E Anaissie

4

1 reference

16 August 2017

J Szymonifka

5

1 reference

16 August 2017

A Hoering

6

1 reference

16 August 2017

N Petty

7

1 reference

16 August 2017

J Crowley

8

1 reference

16 August 2017

J Shaughnessy

9

1 reference

16 August 2017

J Epstein

10

1 reference

16 August 2017

B Barlogie

11

1 reference

16 August 2017

24 April 2008

1 reference

16 August 2017

1 reference

16 August 2017

22

1 reference

16 August 2017

7

1 reference

16 August 2017

1419-1427

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.99

16 August 2017

0 references

cites work

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

The Arkansas approach to therapy of patients with multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

The molecular classification of multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Identification and validation of novel therapeutic targets for multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

A phase 2 study of bortezomib in relapsed, refractory myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Antitumor activity of thalidomide in refractory multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Cytoplasmic immunoglobulin content in multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Nonparametric Estimation from Incomplete Observations

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2008.99

More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2008.99

Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664925

Treatment of multiple myeloma

4 December 2018

1 reference

12 December 2020

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1 reference

12 December 2020

Cytogenetic findings in 200 patients with multiple myeloma

1 reference

12 December 2020

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

12 December 2020

Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

12 December 2020

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications

1 reference

12 December 2020

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

12 December 2020

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2008.99

1 reference

Dimensions Publication ID

16 August 2017

1026708338

0 references

Fatcat ID

release_jvnmvu3vuvbqheb627zf6a3ipy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jvnmvu3vuvbqheb627zf6a3ipy

24 November 2022

mapped directly with Wikidata item

1 reference

16 August 2017

PubMed publication ID

18432260

1 reference